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Independent prognostic value of preoperative serum markers CA 242,
specific tissue polypeptide antigen and human chorionic gonadotrophin beta,
but not of carcinoembryonic antigen or tissue polypeptide antigen in
colorectal cancer
M Carpelan-Holmstrdml, C Haglund', J Lundin', H Alfthan2, U-H Stenman2 and PJ Roberts'
Departments of'Surgery and 2Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland.
Summary The prognostic value ofpreoperative serum concentrations ofcarcinoembryonic antigen (CEA), CA
242, tissue polypeptide antigen (TPA), specific tissue polypeptide antigen (TPS) and human chorionic
gonadotrophin beta (hCG,B) in 251 patients with colorectal cancer (39 Dukes' A, 98 Dukes' B, 56 Dukes' C
and 58 Dukes' D) was investigated. When using the cut-off levels recommended for diagnostic purposes, there
was a significantly longer overall survival in patients with low tumour marker levels compared with patients
with elevated serum levels for all the investigated markers. In Dukes' stage B, C and D CA 242 emerged as a
significant predictor of survival, whereas TPA, TPS and hCG,B showed a value only in Dukes' D.
Unfortunately, no marker provided prognostic information in Dukes' A. In multivariate analysis, entering the
tumour markers as continuous variables, Dukes' stage was the strongest prognostic factor, followed by CA
242. TPS, hCG,B and localisation of the tumour were also independent prognostic factors, whereas age, gender,
CEA and TPA were not.
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Colorectal cancer is a common disease in western countries
and although many patients have resectable primary disease,
recurrence after surgery with curative intent is a common
cause of death. Stage according to the Dukes' classification is
still the strongest prognostic factor to which other prognostic
factors should be compared (Jass et al., 1986; Deans et al.,
1992). The prognostic information provided by the Dukes'
staging system is not available or reliable preoperatively and
also post-operatively there is a need to predict outcome
within each Dukes' stage.
The serum levels of various tumour markers are easily
determined and they may provide prognostic information
preoperatively. They may be of clinical value in selecting the
patients at high risk during follow-up regardless of Dukes'
stage.
Carcinoembryonic antigen (CEA), which is the most used
serological tumour marker in colorectal cancer for diagnosis
and follow-up has also been studied as a prognostic marker,
but its value in predicting outcome still remains controversial
(Dhar et al., 1972; Wanebo et al., 1978; Goslin et al., 1980;
Steele et al., 1982; de Mello et al., 1983; Wolmark et al.,
1984; Briimmendorf et al., 1985; Bogenschiitz et al., 1986;
Moertel et al., 1986; Wiggers et al., 1988; Filella et al., 1992;
Hohenberger et al., 1994; Slentz et al., 1994; Wang et al.,
1994; Lindmark et al., 1995).
CA 242 and tissue polypeptide antigen (TPA) have
recently been shown to be prognostic factors in colorectal
cancer (Lindmark et al., 1995) and TPA was shown to be a
superior prognostic factor to CEA, CA 242 and specific tissue
polypeptide antigen (TPS) (Stahle et al., 1988a; Lindmark et
al., 1995). Human chorionic gonadotropin (hCG) is a
glycoprotein hormone normally secreted by the placenta
and composed of two non-covalently linked molecule
subunits, called ac and /B. Elevated levels of the free ,B-
subunit of hCG (hCG,B) have been found in the serum of
patients with various gastrointestinal malignancies (Alfthan et
al., 1992; Marcillac et al., 1992). The prognostic value of
hCGP in colorectal cancer has not been investigated
previously.
This study was designed to investigate the prognostic value
of preoperatively elevated serum levels of CEA, CA 242,
TPA, TPS and hCG/ in patients with colorectal cancer and
to test the prognostic strength of the different markers
against conventional prognostic factors in a multivariate
analysis.
Patients and methods
Patients
Preoperative serum samples were obtained from 251 patients
with clinically diagnosed and histologically verified colorectal
cancer at the Department of Surgery during 1982-89.
Tumours were classified according to the modified Dukes'
classification (Turnbull et al., 1967). Thirty-nine patients had
Dukes' A, 98 patients Dukes' B, 56 patients Dukes' C and 58
patients Dukes' D colorectal cancer. Colonic and rectal
cancer were found in 149 and 102 patients respectively. There
were 127 men (median age 69 years, range 25-89 years) and
124 women (median age 70 years, range 36-88 years).
Survival data of the patients to the end of 1993 were obtained
from patient records, the Finnish Cancer Registry and the
Population Registry. Altogether 123 patients died from
colorectal cancer during follow-up (median follow-up time
5.1 years).
Assays
Preoperative serum samples were stored at -20°C until
analysed. Serum levels of CEA, CA 242, TPS and TPA were
quantitated by commercially available assays. CEA was
quantitated by a solid-phase radioimmunoassay (Abbott-
Diagnostics, Chicago, IL, USA), CA 242 by a dissociation-
enhanced lanthanide fluoroimmunoassay (DELFIA) (Wallac,
Turku, Finland) and TPS and TPA were quantitated by
immunoradiometric assays (BEKI Diagnostics, Bromma,
Sweden and Sangtec Medical, Bromma Sweden respec-
tively). Serum levels of hCG,B were measured by an
Correspondence: PJ Roberts
Received 2 January 1996; revised 8 March 1996; accepted 17 April
1996Tumour markers and prognosis in colorectal cancer
M Carpelan-Holmstrom et al
immunofluorometric assay (IFMA), as described previously
(Alfthan et al., 1988).
The cut-off levels recommended for diagnostic purposes
used were 5 ng ml- 1 for CEA, 20 U ml-
1 for CA 242,
95 U L- for TPA, 80 U L-' for TPS and 2 pmol I` for
hCG,B. In the multivariate analysis the logarithms of the
marker levels were also entered as continuous variables.
Statistical analysis
Life tables were calculated according to Kaplan and Meier.
Deaths were deaths due to colorectal cancer, whereas
deaths due to other causes were treated by censoring.
Patients were divided into groups having a tumour marker
value above or below the cut-off levels and the respective
survival curves were compared. The median survival was
calculated including the patients who were censored, using
the length of time they were in the study. The statistical
significance of the difference in survival of the groups was
calculated using the log-rank test. When the variable
analysed consisted of three or more ordered categories,
the log-rank test for trend was used. Multivariate survival
analyses were performed with the Cox proportional hazards
model entering the following covariates: age (as a
continuous variable), gender (male, 0; female, 1), Dukes'
stage (as nominal groups), localisation of the tumour
(colonic, 0; rectal, 1), preoperative serum CEA, CA 242,
TPA, TPS and hCGP [the logarithms of the serum levels
were entered as continuous variables or alternatively the
tumour markers were entered as below (0) or above (1) the
cut-off level]. Covariates were selected in a stepwise fashion
(backward to forward), with the use of the maximum
likelihood ratio. The P-value of 0.05 was adopted as the
limit for inclusion of a covariate. The correlation of the
tumour markers was calculated by linear regression using
the logarithms of the serum levels.
Results
Carcinoembryonic antigen (CEA)
The median preoperative serum CEA level was below
5 ng ml-
1 (range <5-9000 ng ml-) (Table I). Sensitivity
of CEA within each Dukes' stage is shown in Table II. The
median survival of the 144 patients with serum levels lower
than 5 ng ml-' was 5.0 years and that of 107 patients with a
higher value 1.8 years. The difference between the survival
curves was highly significant, P>0.0001 [RR 2.4, CI (95%)
1.7- 3.5, X2=23, Figure 1]. When the patients were stratified
by Dukes' stage, CEA was no longer a significant predictor
of survival in any of the subgroups.
CA 242
The median preoperative serum CA 242 level was 11 U ml-'
(range <5-20 000 U ml-') (Table I). Sensitivity of CA 242
within each Dukes' stage is shown in Table II. The median
survival of 157 patients with serum values below 20 U ml-1
was 5.0 years, compared with 1.5 years for 94 patients with
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Figure 1 Life table for patients with colorectal cancer with
preoperative CEA serum levels below (-- - -) or above ( ) the
recommended cut-off level of 5 ng ml-1. The P value between the
survival curves were highly significant (P<0.0001).
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Figure 2 Life table for patients with colorectal cancer with
preoperative CA 242 serum levels below (-
- - -) or above ( )
the recommended cut-off level of 20Uml-l. The P-value between
the survival curves was highly significant (P<0.0001).
Table I Median and range of preoperative serum levels of CEA, CA242, TPA, TPS and hCG,B in 251 patients with colorectal cancer
Number of CEA CA 242 TPA TPS hCG/
patients (ngml-) (Umr') (Ur1) (Ur1) (pmolrl')
Dukes' A 39 <5(<5-11) 8.1 (<5-140) 64 (17-170) 39 (29-160) 0.79 (<0.5-4.5)
Dukes' B 98 <5(<5-1500) 9.0 (<5-1000) 85 (24-536) 42 (29-800) 0.74 (<0.5-6.2)
Dukes' C 56 <5(<5-300) 6.5 (<5-270) 88 (33-910) 40 (29-740) 0.81 (<0.5-4.3)
Dukes' D 58 61 (<5-9000) 100 (<5-20000) 335 (34-14000) 120 (29-13 000) 1.4 (<0.5-160)
Table II Sensitivity of CEA, CA242, TPA, TPS and hCG,B in patients with colorectal cancer
Dukes' A Dukes' B Dukes' C Dukes' D All
Cut-off value (39 patients) (98 patients) (56 patients) (58 patients) (251 patients)
CEA 5ngml-' 26% 32% 39% 76% 43%
CA242 20Uml-' 26% 26% 38% 66% 37%
TPA 95 U1-' 15% 37% 43% 83% 45%
TPS 80Ul-1 15% 17% 18% 57% 26%
hCG,B 2pmoll-' 5% 12% 11% 40% 17%serum levels above that level. The difference between the
survival curves was highly significant, P<0.0001 [RR 2.9, CI
(95%) 2.1-4.2, x2= 35, Figure 2]. Significant differences
between the survival curves were seen also within Dukes'
stage B, C and D (P=0.036, P=0.03 and P=0.0091
respectively), whereas in Dukes' stage A the difference was
not significant (P=0.67).
Tissue polypeptide antigen (TPA)
The median preoperative serum level was 90 U I` (range
17-13 600 U l-1) (Table I). Sensitivity of TPA within each
Dukes' stage is shown in Table II. There were 137 patients
with serum TPA levels below 95 U I` and their median
survival was 5.0 years, whereas the median survival of the 114
patients with serum levels above this level was 1.5 years. The
difference between the survival curves was highly significant,
P<0.0001 [RR 2.5, CI (95%) 1.8-3.6, X2=26, Figure 3].
When the patients were analysed within Dukes' stages, there
was a difference between the survival curves seen in Dukes' D
cancer (P=0.027), whereas the differences were not
significant in earlier stages.
Specific tissue polypeptide antigen (TPS)
The median preoperative serum level was 43 U 1` (range
29-12 700 U I` (Table I). Sensitivity within each Dukes'
stage is shown in Table II. The median survival of the 185
patients with serum TPS levels below 80 U I` was 7.9 years
compared with 1.0 year for the 66 patients with serum values
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above this level. The difference between the survival curves
was highly significant, P<0.0001 [RR 2.8, CI (95%) 2.0-4.1,
x2=30, Figure 4]. When dividing the patients according to
Dukes' stage, there was a difference in survival in Dukes' D
cancer (P=0.039), but not in other stages.
Human chorionic gonadotrophin beta (hCGJ3)
The median preoperative serum level of hCGJ was
0.79 pmol 1` (range <0.5-160 pmol l-1) (Table I). Sensi-
tivity ofhCGP within each Dukes' stage is shown in Table II.
There were 208 patients with serum levels below 2 pmol I'
and their median survival was 7.9 years compared with 1.0
year for 43 patients with serum levels above this level. The
difference between the survival curves was highly significant,
P<0.0001 [RR 2.9, CI (95%) 2.0-4.4, X2=27, Figure 5]. In
Dukes' D cancer the difference between the survival curves
was significant (P=0.047). In other stages the difference was
not significant, although the difference approached signifi-
cance in Dukes' B cancer (P=0.064).
Comparison of the tumour markers
When comparing the tumour markers pairwise by linear
regression using the logarithms of the serum levels, TPA and
TPS showed strong correlation (R=0.80), whereas the
correlation between the other tumour markers was lower
(Table III). In multivariate analysis, Dukes' stage emerged as
the strongest prognostic factor. When the tumour markers
were entered into the model dichotomised at the recom-
mended cut-off level, Dukes' stage was followed by CA 242
(P<0.0001), TPS (P=0.0002), age (P=0.0066) and localisa-
tion ofthe tumour (P=0.029). CEA, hCG,B, TPA and gender
did not emerge as independent prognostic factors. When
entering the logarithms of the serum tumour marker levels as
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Figure 3 Life table for patients with colorectal cancer with
preoperative TPA serum levels below (- - - -) or above ( ) the
recommended cut-off level of 95 Ul-l. The P-value between the
survival curves was highly significant (P<0.0001).
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Figure 4 Life table for patients with colorectal cancer with
preoperative TPS serum levels below t- - - -) or above ( ) the
recommended cut-off level of 80U1- . The P-value between the
survival curves was highly significant (P<0.0001).
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Figure 5 Life table for patients with colorectal cancer with
preoperative hCGB,B serum levels below (- - - -) or above ( )
the recommended cut-offlevel of2p moll-1. The P-value between
the survival curves was highly significant (P<0.0001).
Table HI Correlation (R) of the different tumour markers,
calculated by linear regression using the logarithms of the serum
levels
R P-value
TPA vs TPS 0.80 <0.0001
CEA vs CA242 0.59 <0.0001
CEA vs TPS 0.56 <0.0001
CEA vs TPA 0.54 <0.0001
CA242 vs TPA 0.49 <0.0001
CA242 vs TPS 0.47 <0.0001
TPA vs hCG,B 0.33 0.0001
CEA vs hCG,B 0.26 <0.0001
CA242 vs HCGf 0.24 0.0002
TPS vs hCG,B 0.19 0.0027Tunow nmakers and prognosi n comrecal cancer
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Table IV Stepwise multivariate analysisa of prognostic covanrates
of survival in 251 patients with colorectal cancer
Covariate pb RHu CI (95% )d
Dukes' stage
Be NS 1.5 0.67-3.3
CC <0.0001 5.4 2.5-12
De <0.0001 11 4.8-25
CA242f <0.0001 1.6 1.3-2.1
TjPSf 0.0007 1.9 1.3-2.8
hCG#f 0.0017 1.8 1.3-2.7
Tumour localisationg 0.014 1.6 1.1-2.3
Ageh NS
Gender NS
CEAf NS
TPAf NS
aCox proportional hazards model. bSignificance level. NS, non-
significant. cRelative hazard. dConfidence interval at 95% level.
'Dukes' stages entered as nominal groups and compared with Dukes'
A stage. fThe logarithms ofthe preoperative serum levels were entered
as continuous variables. gLocalisation as category (rectal. 0; colonic.
1). hAge was entered as a continuous variable. 'Gender entered as
category (male. 0: female. 1).
continuous variables in the Cox model. Dukes' stage was
followed by CA 242 (P<0.0001), TPS (P=0.0007), hCGf
(P=0.0017) and tumour localisation (P=0.0135), whereas
CEA. TPA, age and gender dropped out from the model as
not being independent prognostic factors (Table TV).
Discussion
This study confirmed that Dukes' stage is the strongest
prognostic factor in colorectal cancer. However, when
neoadjuvant treatment is used there is an increasing need to
predict outcome already before surgery. For post-operative
chemotherapy there is also a need to select patients with
unfavourable prognosis. especially in Dukes' C cancer. Serum
tumour markers could be useful for this purpose. Most other
prognostic markers require tissue samples and are therefore
available only after surgery (or biopsy) and the reproduci-
bility of the results may be variable. In this aspect serum
tumour markers differ from other prognostic tests, as the
results are available preoperatively and they are reproducible
and easily interpreted.
All the investigated tumour markers provided prognostic
information. An elevated serum level ofany ofthe investigated
tumour markers was strongly related to disseminated disease
and poor survival. CA 242 was the only marker that provided
prognostic information within Dukes' B and C colorectal
cancer. In Dukes' D colorectal cancer not only CA 242 but
also TPA, TPS and hCGfl showed a prognostic value. In
contrast to many previous reports, CEA did not provide
significant prognostic information in addition to stage of
disease (Wanebo et al., 1978: Wolmark et al.. 1984:
Brummendorf et al., 1985; Slentz et al., 1994; Wang 1994:
Lindmark et al., 1995). In multivariate analysis CA 242, TPS
and hCGJ were independent prognostic factors, when entering
the serum tumour marker levels as continuous values. When
entering the serum tumour marker levels as normal or elevated
(dichotomised) in the model, hCGf dropped out. In a recent
report CA 242 was, as in our study, shown to be a prognostic
factor (Lindmark et al., 1995). However, in that report TPA
and CEA were found to be superior to CA 242, and in that
respect the results differed markedly from our results. In an
earlier study by the same group, TPA was found to be a
superior prognostic factor to CEA and CA 50 in rectal cancer
(StAhle et al.. 1988b).
Previously., CA 242 has been reported to be a valuable
additional diagnostic tool preoperatively and in the follow-up
of patients with colorectal cancer (Kuusela et al., 1991:
Nilsson et al., 1992; Hall et al., 1994; Carpelan-Holmstr6m et
al., 1995). The results of this study further support previous
findings, showing that the preoperative CA 242 serum level is
an independent prognostic factor.
We conclude that the Dukes' stage is still the strongest
prognostic factor in colorectal cancer and that CA 242
provides additional prognostic information within Dukes'
stages B, C and D. TPS and hCGf were also shown to be
independent prognostic factors but the difference in survival
was significant only in advanced disease. The promising
results on the prognostic value of CA 242 needs to be
evaluated in prospective studies on colorectal cancer.
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